NEWS
The 2025 AD Scientific Index is here—explore updated university and researcher rankings!
New! Young University / Institution Rankings 2025
New! The 2025 Edition of the AD Scientific Index is now live!
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
"Exciting Update! The 2025 Edition of the AD Scientific Index is now live!
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Top Lists
Alhassane Diallo
University of Science & Technology of China - Hefei / China
Others
AD Scientific Index ID: 5098690
中国科学技术大学
Edit Form
Registration, Add Profile,
Premium Membership
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Alhassane Diallo's MOST POPULAR ARTICLES
1-)
PIK3CA pathway mutations predictive of poor response following standard radiochemotherapy±cetuximab in cervical cancer patientsA de la Rochefordiere, M Kamal, A Floquet, L Thomas, P Petrow, T Petit, ...Clinical Cancer Research 21 (11), 2530-2537, 2015602015
2-)
Phase II trial of bevacizumab in combination with temozolomide as first-line treatment in patients with metastatic uveal melanomaS Piperno-Neumann, A Diallo, MC Etienne-Grimaldi, FC Bidard, ...The oncologist 21 (3), 281-282f, 2016502016
3-)
Hydrosorb® versus control (water based spray) in the management of radio-induced skin toxicity: Results of multicentre controlled randomized trialL Bazire, I Fromantin, A Diallo, B de la Lande, V Pernin, R Dendale, ...Radiotherapy and Oncology 117 (2), 229-233, 2015352015
4-)
BEVATEM: Phase II study of bevacizumab (B) in combination with temozolomide (T) in patients (pts) with first-line metastatic uveal melanoma (MUM): Final results.S Piperno-Neumann, V Servois, FC Bidard, P Mariani, C Plancher, ...Journal of Clinical Oncology 31 (15_suppl), 9057-9057, 2013142013
5-)
Hydrosorb (R) versus control (water based spray) in the management of radiodermatitis: Results of multicentre controlled randomized trialL Bazire, I Fromantin, A Diallo, B De la Lande, V Pernin, R Dendale, ...EUROPEAN JOURNAL OF CANCER 57, S48-S48, 20162016
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept